Sudarshan Pharma Industries Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹217 Cr +28.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
SP

Sudarshan Pharma Industries Ltd

Q4 FY26Chemicals & Petrochemicals

Sudarshan Pharma Industries Q4 FY26: Revenue ₹220.92 Cr, EBITDA margin 9.14%

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹221Cr
+36.7% YoY
+31.5% QoQ
Net profit
₹11Cr
+53.8% YoY
+174.7% QoQ
Margin
9.14%
−0.7 pp YoY
+2.7 pp QoQ

Sudarshan Pharma Industries Ltd Q4 FY26 key numbers

Revenue
Revenue from Operations for Q4 March 2026: ₹220.92 Cr.

As stated in Sudarshan Pharma Industries Ltd's Q4 FY26 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.

Based on Sudarshan Pharma Industries Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹39
Market cap₹990 Cr
P/E39.4

The short version

Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) - Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data) - Year-on-year growth inf Quarterly EBITDA (Q4 March 2026): INR 20.19 Cr with an EBITDA margin of 9.14%.

From Sudarshan Pharma Industries Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41)
  • Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data)
  • Year-on-year growth inferred for Q4 Mar 2026 vs Mar 2025 is approximately 31.4% (₹220.92 Cr vs ₹168.01 Cr)
  • FY 2026 Revenue from Operations: ₹703.06 Cr vs FY 2025 ₹505.05 Cr, a 39.2% increase (Page 42)
  • Outlook for FY 26-27 export turnover target: Minimum ₹100 Cr (Page 13)

2 more points from Sudarshan Pharma Industries Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Nutraceuticals Plant project: Rs. 2.5 Cr. project cost with Rs. 1.15 Cr. machinery cost (2019-2020).
  • Oral liquid and capsule manufacturing unit erected at Palghar (2021-2022).
  • Vitamin B1 and B6 manufacturing under Production Linked Incentive (PLI) schemes; new products developed and to be first made in India (2021-2022).
  • New unit development in Palghar (2023-2024).
  • Acquisitions: Ratna Lifesciences & 51% of Ishwari Healthcare (2024-2025).
  • Proposed allotment of FCCB worth 20 Million USD (2025-2026).

2 more points from Sudarshan Pharma Industries Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Sudarshan Pharma Industries Ltd said on order book & pipeline — free account, 30 seconds.

Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sudarshan Pharma Industries Ltd Q4 FY26 results — key figures

Sudarshan Pharma Industries Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue221162+36.7%168+31.5%
Operating profit (EBITDA)2016+26.8%11+85.8%
Operating margin9.14%9.86%-0.7 pp6.47%+2.7 pp
Profit before tax1610+58.8%5+202.1%
Net profit (PAT)117+53.8%4+174.7%
EPS (₹)0.450.31+45.2%0.18+150%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Sudarshan Pharma's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Paragon Fine (Q4 FY26)

    Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p

  • IVP (Q4 FY26)

    Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector

  • Vishnu Chemicals (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sudarshan Pharma Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sudarshan Pharma Industries Ltd Q4 FY26 results?

Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) - Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data) - Year-on-year growth inf Quarterly EBITDA (Q4 March 2026): INR 20.19 Cr with an EBITDA margin of 9.14%.

What is Sudarshan Pharma Industries Ltd share price analysis?

Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 39.4 with a market cap of ₹990 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Pharma Industries Ltd planning capital expenditure?

Nutraceuticals Plant project: Rs. 2.5 Cr. project cost with Rs. 1.15 Cr. machinery cost (2019-2020).

Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.